EMEA-003217-PIP01-22 - paediatric investigation plan

Modakafusp Alfa

Key facts

• Active Substance:
  Modakafusp Alfa
• Therapeutic area:
  Oncology
• Decision number:
  P/0282/2022
• PIP number:
  EMEA-003217-PIP01-22
• Pharmaceutical form(s):
  All pharmaceutical forms
• Condition(s) / indication(s):
  Treatment of Multiple Myeloma
• Route(s) of administration:
  All routes of administration
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  11/08/2022

Decision

P/0282/2022 : EMA decision on the granting of a product specific waiver for modakafusp alfa (EMEA-003217-PIP01-22)

AdoptedReference Number: EMA/629079/2022